Could a low-dose definitive radiation therapy be the optimal treatment for choroidal hemangioma?
Choroidal hemangioma is a benign vascular tumor presenting in circumscribed and diffused forms, often leading to profound visual loss. In symptomatic cases, 50% of patients present with a visual acuity of 20/200 or worse in the long term if untreated [1]. The management of circumscribed choroidal hemangioma (CCH) has evolved over the past several decades from laser photocoagulation, transpupillary thermotherapy, and radiotherapy to the wide usage of recent photodynamic therapy (PDT). (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 17, 2024 Category: Radiology Authors: Li Wang, Tianci Tang, Jie Wang, Tong Lin, Yi Li, Xinmao Song Tags: Original Article Source Type: research
Assessing radiation-induced carotid artery injury using ultrasound in patients with head and neck cancer
Head and neck cancers (HNC) are among the most prevalent malignant tumors worldwide. They encompass malignancies of the upper respiratory tract and gastrointestinal system, including nasopharyngeal carcinoma, laryngeal carcinoma, tongue carcinoma, parotid gland carcinoma, and others [1]. The development of HNC is closely related to smoking, excessive drinking, chewing of betel nuts, and viral infection (HBV/HPV). The treatment of HNC includes surgery, radiotherapy (RT), chemotherapy, and immunotherapy. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 17, 2024 Category: Radiology Authors: Zhuangzhuang Zheng, Yingying Shen, Jing Su, Xiaorui Ji, Qiang Zhang, Qin Zhao, Xin Jiang Tags: Original Article Source Type: research
Predictive factors for radiation-induced pituitary damage in pediatric patients with brain tumors
Multiple studies have demonstrated hypothalamic –pituitary dysfunction in survivors of childhood and adolescent brain tumors. Hypothalamic-pituitary dysfunction may reflect direct injury by the tumor itself or by surgery, as well as treatment-induced damage, mainly due to cranial irradiation. Other risk factors for pituitary hormone deficiencie s include concurrent chemotherapy and young age at the time of irradiation [1–7]. Hypothalamic-pituitary dysfunction secondary to radiation is time-dependent, with both increased incidence and severity of hormonal deficits with longer follow-up [8]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 17, 2024 Category: Radiology Authors: Larisa Gorenstein, Shai Shrot, Michal Ben-Ami, Eve Stern, Michal Yalon, Chen Hoffmann, Shani Caspi, Michal Lurye, Amos Toren, Gadi Abebe-Campino, Dalit Modan-Moses Tags: Original Article Source Type: research
European Society of Radiotherapy and oncology (ESTRO) strategy 2024 –2026: Growth and diversification in a rapidly changing world
In 2019, the European Society of Radiotherapy and Oncology (ESTRO) published its 2030 Vision summarised as “Radiation Oncology, Optimal Health, For All, Together” to be achieved through the four pillars of (i) translating research into practice; (ii) strengthening the profession; (iii) strengthening the Society, and (iv) strengthening partnerships [1]. In 2020, the COVID-19 pandemic, beyond its immed iate and devastating human effects, presented profound challenges to healthcare, and to scientific societies supporting healthcare professionals, their communities and patients. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 17, 2024 Category: Radiology Authors: A.M. Kirby, M. Guckenberger, B.J. Slotman, C.H. Clark, J.G. Eriksen, U. van der Heide, S. De Ioanna, C. Gasparotto, A.J. Cortese, on behalf of the ESTRO Board of Directors Tags: Original Article Source Type: research
Risk factors associated with the development of osteoradionecrosis (ORN) in Head and Neck cancer patients in Ireland: A 10-year retrospective review
Over 700 cases of Head and Neck cancer (HNC) are diagnosed in Ireland each year [1]. Recommended treatment options for HNC include surgery, radiation therapy (RT), and systemic therapy [2]. One of the most serious long-term complications of radiotherapy in HNC patients is osteoradionecrosis (ORN) [3]. Clinical presentations of ORN include persistent pain, chronic bone exposure, pus secretion, radiographic bone changes, pathological fracture, inflammation, and roughness [4]. Patients suffering from ORN experience considerable deterioration in their quality of life owing to chronic pain, infection, dysphagia, and oro-facial ...
Source: Radiotherapy and Oncology - April 17, 2024 Category: Radiology Authors: Kathleen T. Fitzgerald, Ciara Lyons, Andrew England, Mark F. McEntee, Annemarie Devine, Theresa O'Donovan, Eleanor O'Sullivan Tags: Original Article Source Type: research
Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer
Despite advances in the multi-disciplinary management of squamous cell carcinoma of the head and neck, a significant proportion of patients still experience local –regional recurrence after radiation therapy. For patients who are not candidates for salvage surgery, re-irradiation has long been suggested to improve outcomes [1–3]. However, the evidence in favor of re-irradiation is based almost entirely on single-arm studies, most of which have established relatively modest rates of local control [4–6]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 16, 2024 Category: Radiology Authors: Allen M. Chen, Jeremy P. Harris, Rupali Nabar, Tjoson Tjoa, Yarah Haidar, William B. Armstrong Tags: Original Article Source Type: research
A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE)
More than half of the patients with head and neck squamous cell carcinomas (HNSCC) are diagnosed at a locally advanced stage (LA) [1]. The standard of care for LAHNSCC treatment is concurrent chemoradiation with curative intent. Although this locoregionally targeted therapy is effective in the majority of patients, locoregional recurrences are four-fold more common than metastases [2]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 16, 2024 Category: Radiology Authors: Anna Liza M.P. de Leeuw, Jordi Giralt, Yungan Tao, Sergi Benavente, Thanh-V ân France Nguyen, Frank J.P. Hoebers, Ann Hoeben, Chris H.J. Terhaard, Lip Wai Lee, Signe Friesland, Roel J.H.M. Steenbakkers, Lisa Tans, Jolien Heukelom, Mutamba T. Kayembe, Sim Tags: Original Article Source Type: research
Comparison of 3-year local control using DAHANCA radiotherapy guidelines before and after implementation of five millimetres geometrical GTV to high-dose CTV margin
Primary radiotherapy is the preferred anatomy-preserving treatment for squamous cell carcinomas in the head and neck region (HNSCC), excluding carcinomas in the oral cavity or certain localised oropharyngeal/laryngeal cancers amenable to surgery[1,2]. Platinum-based chemo-radiotherapy (CRT) using IMRT/VMAT techniques is the contemporary standard for loco-regionally advanced HNSCC, with a five-year risk of local and regional failures of 23.5 % and 20.2 %, respectively, using altered fractionation regimes [3]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 16, 2024 Category: Radiology Authors: Ruta Zukauskaite Ruta, Morten Horsholt Kristensen, Jesper Grau Eriksen, J ørgen Johansen, Eva Samsøe, Lars Johnsen, Camilla Kjær Lønkvist, Cai Grau, Christian Rønn Hansen Tags: Original Article Source Type: research
Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer
Radiotherapy (RT) is an integral component of nasopharyngeal cancer (NPC) management. Advanced RT techniques such as intensity-modulated radiotherapy (IMRT) have improved the anatomical precision of local treatment for primary NPC.[1] Despite this, around 20 –30 % of patients develop local recurrence and/or distant metastases.[2] Additionally, up to 50 % of patients in remission experience RT-induced late toxicities.[3] Current radiation dose protocols are uniformly standardized at 66–70 Gy for gross disease and 54–60 Gy for elective nodal regions, despite substantial heterogeneity in treatment response. (Sou...
Source: Radiotherapy and Oncology - April 16, 2024 Category: Radiology Authors: Chi Leung Chiang, Kenneth Sik Kwan Chan, Huaping Li, Wai Tong Ng, James Chung Hang Chow, Horace Cheuk Wai Choi, Ka On Lam, Victor Ho Fun Lee, Roger Kai Cheong Ngan, Anne Wing Mui Lee, Steven A Eschrich, Javier F Torres-Roca, Jason Wing Hon Wong Tags: Original Article Source Type: research
Postoperative radiotherapy results in 192 epithelial thymic tumours patients with 10 years of follow-up
Thymic epithelial tumours (TET) are rare and malignant tumours of the mediastinum. Due to their rarity, studies inclusion periods are long and treatment modalities have varied across time. Actual recommendations are not robust due to the lack of prospective studies. In addition, thymomas have a slow evolution and large series with a long-term follow-up are scarce [1 –5]. In France, treatment recommendations for the past 10 years, have been based on ESMO (European Society for Medical Oncology) and RYHTMIC (Réseau tumeurs THYMiques et Cancer), a French network mandated to systematically discuss every case of TET in Fran...
Source: Radiotherapy and Oncology - April 11, 2024 Category: Radiology Authors: Hugo Lopez, Angela Botticella, Farid Belkhir, Benjamin Besse, Elie Fadel, Olaf Mercier, Antonin Levy, C écile Le Péchoux Tags: Original Article Source Type: research
Long-term survival outcomes and quality of life of image-guided proton therapy for operable stage I non-small cell lung cancer: A phase 2 study
Definitive radiation therapy (RT), especially stereotactic body RT (SBRT), is an important treatment option for stage I non-small cell lung cancer (NSCLC). Surgical resection is the first-line management for operable patients, with SBRT recommended for medically inoperable patients or those who refuse surgery [1]. A recent pooled randomized and propensity-matched prospective study reported that SBRT was comparable to surgery in operable patients [2]. As patient preferences diversify, offering effective non-surgical options in the treatment decision process holds considerable clinical value. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 11, 2024 Category: Radiology Authors: Koichiro Nakajima, Masanosuke Oguri, Hiromitsu Iwata, Yukiko Hattori, Shingo Hashimoto, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Kenji Akita, Fumiya Baba, Hiroyuki Ogino, Akio Hiwatashi Tags: Original Article Source Type: research
Comparing the effects of irradiation with protons or photons on neonatal mouse brain: Apoptosis, oncogenesis and hippocampal alterations
Proton therapy offers a favorable depth-dose deposition with the advantage of sparing healthy tissues, therefore potentially reducing radiation side effects. Proton therapy is commonly used to treat a range of tumors including central nervous tumors, such as medulloblastoma (MB) [1]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 10, 2024 Category: Radiology Authors: Daniela Giovannini, Francesca Antonelli, Arianna Casciati, Cinzia De Angelis, Maria Denise Astorino, Giulia Bazzano, Emiliano Fratini, Alessandro Ampollini, Monia Vadrucci, Evaristo Cisbani, Paolo Nenzi, Luigi Picardi, Anna Saran, Carmela Marino, Mariater Tags: Original Article Source Type: research
Re-irradiation for recurrent intracranial meningiomas: Analysis of clinical outcomes and prognostic factors
Intracranial meningiomas are among the most frequent primary brain tumors [1]. Surgery and radiotherapy (RT) represent the most frequent approaches. Most patients with WHO grade 1 meningiomas at favorable locations, e.g. convexity meningiomas, can be cured by surgery. RT is classically prescribed in the adjuvant setting for subtotally resected tumors or those with grade 2 and 3 tumors [2 –5]. Conversely, for those patients who refuse surgery or in case of lesions in critical locations (e.g. skull base meningiomas) RT represents the primary curative treatment [6]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 6, 2024 Category: Radiology Authors: Isacco Desideri, Ilaria Morelli, Marco Banini, Daniela Greto, Luca Visani, Filippo Nozzoli, Saverio Caini, Alessandro Della Puppa, Lorenzo Livi, Zeno Perini, Emanuele Zivelonghi, Giorgia Bulgarelli, Valentina Pinzi, Pierina Navarria, Elena Clerici, Marta Tags: Original Article Source Type: research
Brachytherapy for rhabdomyosarcoma: Survey of international clinical practice and development of guidelines
Brachytherapy can be a highly effective treatment with very limited morbidity for some carefully selected children with rhabdomyosarcoma (RMS). However, access may be limited by the need for highly specialized experienced teams that are needed to deliver the service [1]. RMS is the most common soft tissue sarcoma of childhood, accounting for around 3.5 % of all malignant diseases in children [2,3]. RMS derives from embryonal mesenchyme and can arise at almost any anatomical site. Current multimodal treatment strategies including chemotherapy, surgery, and radiotherapy achieve an overall 5-year survival rate of 80 % [4...
Source: Radiotherapy and Oncology - April 6, 2024 Category: Radiology Authors: Raquel D ávila Fajardo, Giovanni Scarzello, Mark N Gaze, Tom Boterberg, Alison Cameron, Joerg Fuchs, Florent Guérin, Peter Hoskin, Matthew J Krasin, Petra Kroon, Henriette Magelssen, Claes Mercke, Johannes H.M. Merks, Frank Paulsen, Pascal Pommier, Moni Tags: Original Article Source Type: research
Reirradiation for recurrent gynecologic cancer using high-dose-rate brachytherapy in Japan: A multicenter survey on practice patterns and outcomes
Radiotherapy (RT) plays an essential role in treatment of gynecological cancers, including cervical, endometrial, vulvar and vaginal cancers, and development of RT modalities, including chemoradiotherapy (CRT) and three-dimensional image-guided brachytherapy (3D-IGBT), has led to improved outcomes [1,2]. However, recurrence of gynecological cancer within the RT field remains as a significant clinical challenge. Even in well-controlled prospective clinical trials, locoregional failure occurs in about 8 % of patients with cervical cancer after definitive CRT with MRI-guided adaptive brachytherapy [2] and in about 6 % of...
Source: Radiotherapy and Oncology - April 5, 2024 Category: Radiology Authors: Fumiaki Isohashi, Ken Yoshida, Naoya Murakami, Koji Masui, Shunichi Ishihara, Yu Ohkubo, Yuko Kaneyasu, Rumiko Kinoshita, Tadayuki Kotsuma, Yuji Takaoka, Eiichi Tanaka, Ayaka Nagao, Kazuhiko Ogawa, Hideya Yamazaki Tags: Original Article Source Type: research
